Amanda Feilding

Amanda Feilding, also known as the Countess of Wemyss and March, was a British aristocrat, student of comparative religion and mysticism, and advocate for psychedelic research and drug-policy reform. Her significance lies in the unusual combination of personal experimentation, sustained institutional work, and strategic influence that helped launch a modern effort to study psychedelic experience with brain-imaging technology. In 2005, she recognized the potential of Robin Carhart-Harris’s plan to connect psychoanalysis with neuroscience and helped direct him toward David Nutt, bringing an aspiring researcher, a potential funder, and an established psychopharmacology laboratory into alignment.

Background and intellectual interests

Born in 1943, Feilding came from an aristocratic family, with descent from the House of Habsburg and two of Charles II’s illegitimate children. Her social position was striking, but it did not define the limits of her interests. She studied comparative religion and mysticism and developed a longstanding interest in altered states of consciousness. A particular focus was the relationship between blood flow to the brain and changes in mental life.

Feilding believed that the adoption of upright posture had compromised cerebral circulation in human beings. She also believed that LSD could improve cognitive function and facilitate higher states of consciousness by increasing circulation to the brain. These were her theories, not conclusions established by the research described here. They nevertheless gave her a concrete scientific question: whether claims about psychedelic effects and brain function could be examined through research rather than left as speculation.

Trepanation and public advocacy

Before her work shifted toward psychedelic science, Feilding pursued trepanation, the practice of making an opening in the skull. She believed the procedure could improve cerebral blood circulation and thereby support higher states of consciousness. After failing to find a professional willing to perform it, she trepanned herself in 1970. She documented the procedure in the short film Heartbeat in the Brain and subsequently stood for Parliament twice, campaigning on a platform that proposed trepanation as part of national health care.

The episode made her unconventionality unusually visible, but the account also distinguishes eccentricity from a lack of seriousness. Feilding’s later work on drug research and drug-policy reform is characterized as strategic and productive. Over time, her focus moved away from trepanation and toward the possible effects of psychedelics on brain function. The shift retained a through-line: she continued to investigate ways of altering consciousness, while moving toward a research and policy framework capable of engaging those questions publicly.

The Beckley Foundation and the research opening

In 1998, Feilding established the Beckley Foundation to study the effects of psychoactive substances on the brain and to lobby for drug-policy reform. The foundation took its name from Beckley Park, the Tudor manor in Oxfordshire where she had grown up. By 2005, the organization gave her a platform from which to consider research proposals, rather than treating her interest in psychedelics only as a personal pursuit.

That year, Robin Carhart-Harris completed a master’s degree in psychoanalysis and began looking for a route into psychedelic neuroscience. He approached Feilding first. She invited him to lunch at Beckley Park, where he described his ambition to bring research into LSD and Freud together. Feilding immediately saw the project’s potential and the opportunity it offered to test her own ideas about cerebral blood circulation. She indicated that the foundation might fund the work and advised Carhart-Harris to contact David Nutt, then a professor at the University of Bristol and her ally in drug-policy reform.

The connection mattered because the proposed research required more than an interest in psychedelics. Carhart-Harris wanted to use modern brain-imaging methods to investigate mental processes associated with psychoanalysis; Feilding could offer a possible source of support and a relevant research question; and Nutt had the psychopharmacology expertise and laboratory setting in which such work could proceed. Their convergence in England in 2005 helped a controversial, improbable project get off the ground. The research that followed at Imperial College London used psychedelics and scanning technologies to investigate the brain correlates of psychedelic experience.

Personal use and public credibility

Feilding also used LSD in her own life, regarding it as a kind of brain tonic and favoring a dose she believed could increase creativity and enthusiasm while leaving control intact. She once placed that daily dose at 150 micrograms, a quantity well above a microdose. The account notes that frequent LSD use can produce tolerance, so the effects of that amount could vary; the figure is therefore part of Feilding’s reported practice, not a general recommendation or a settled measure of its effects.

She was frank about the reputational burden her circumstances could create in a scientific debate: she was a drug user, lived in a large house, and had trepanned herself. Her awareness of that combination shows her understanding that advocacy and personal biography could complicate the reception of psychedelic research. Yet she did not retreat from the work. Through the Beckley Foundation, her drug-policy campaigning, and her early support for Carhart-Harris, she helped turn a personal and theoretical interest in altered consciousness into a research proposal connected to an established scientific laboratory.